SARS-CoV-2 variants and ending the COVID-19 pandemic

doi:10.1016/S0140-6736(21)00370-6

. 2021 Mar 13;397(10278):952-954.

doi: 10.1016/S0140-6736(21)00370-6. Epub 2021 Feb 11.

SARS-CoV-2 variants and ending the COVID-19 pandemic

Arnaud Fontanet¹, Brigitte Autran², Bruno Lina³, Marie Paule Kieny⁴, Salim S Abdool Karim⁵, Devi Sridhar⁶

Affiliations

¹ Institut Pasteur, Emerging Diseases Epidemiology Unit, Paris 75015, France; Conservatoire National des Arts et Métiers, PACRI Unit, Paris, France. Electronic address: fontanet@pasteur.fr.
² Sorbonne-Université, Paris, France; UMR-S Inserm/UPMC 1135, CIMI-Paris (Centre de Recherches Immunité Maladies Infectieuses), Paris, France.
³ CNR des Virus des Infections Respiratoires, Institut des Agents Infectieux, Hospices Civils de Lyon, Lyon, France; Virpath, Centre International de Recherche en Infectiologie, Université de Lyon, Inserm U1111, CNRS UMR5308, École Normale Supérieure de Lyon, UCBL, Lyon, France.
⁴ Inserm, Paris, France.
⁵ Centre for the AIDS Programme of Research in South Africa (CAPRISA), Durban, South Africa; Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, NY, USA.
⁶ Usher Institute of Population Health Sciences and Informatics, Edinburgh Medical School, University of Edinburgh, Edinburgh, UK.

PMID: 33581803
PMCID: PMC7906631
DOI: 10.1016/S0140-6736(21)00370-6

SARS-CoV-2 variants and ending the COVID-19 pandemic

Arnaud Fontanet et al. Lancet. 2021.

. 2021 Mar 13;397(10278):952-954.

doi: 10.1016/S0140-6736(21)00370-6. Epub 2021 Feb 11.

Authors

Arnaud Fontanet¹, Brigitte Autran², Bruno Lina³, Marie Paule Kieny⁴, Salim S Abdool Karim⁵, Devi Sridhar⁶

Affiliations

¹ Institut Pasteur, Emerging Diseases Epidemiology Unit, Paris 75015, France; Conservatoire National des Arts et Métiers, PACRI Unit, Paris, France. Electronic address: fontanet@pasteur.fr.
² Sorbonne-Université, Paris, France; UMR-S Inserm/UPMC 1135, CIMI-Paris (Centre de Recherches Immunité Maladies Infectieuses), Paris, France.
³ CNR des Virus des Infections Respiratoires, Institut des Agents Infectieux, Hospices Civils de Lyon, Lyon, France; Virpath, Centre International de Recherche en Infectiologie, Université de Lyon, Inserm U1111, CNRS UMR5308, École Normale Supérieure de Lyon, UCBL, Lyon, France.
⁴ Inserm, Paris, France.
⁵ Centre for the AIDS Programme of Research in South Africa (CAPRISA), Durban, South Africa; Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, NY, USA.
⁶ Usher Institute of Population Health Sciences and Informatics, Edinburgh Medical School, University of Edinburgh, Edinburgh, UK.

PMID: 33581803
PMCID: PMC7906631
DOI: 10.1016/S0140-6736(21)00370-6

No abstract available

PubMed Disclaimer

Cited by

Evaluating vaccination timing, hesitancy and effectiveness to prevent future outbreaks: insights from COVID-19 modelling and transmission dynamics.
Tanwar K, Kumawat N, Tripathi JP, Chauhan S, Mubayi A. Tanwar K, et al. R Soc Open Sci. 2024 Nov 13;11(11):240833. doi: 10.1098/rsos.240833. eCollection 2024 Nov. R Soc Open Sci. 2024. PMID: 39539502 Free PMC article.
Generation and capture of naphthoquinonynes: a new frontier in the development of trypanocidal quinones via aryne chemistry.
Figueroa LPR, de Carvalho RL, Almeida RG, Paz ERS, Diogo EBT, Araujo MH, Borges WS, Ramos VFS, Menna-Barreto RFS, Wood JM, Bower JF, da Silva Júnior EN. Figueroa LPR, et al. RSC Med Chem. 2024 Sep 26. doi: 10.1039/d4md00558a. Online ahead of print. RSC Med Chem. 2024. PMID: 39512946 Free PMC article.
Neutralizing Antibodies against 10 SARS-CoV-2 Variants at Two Years Post-COVISHIELD Vaccination with Special Reference to Omicron Subvariants and Booster Administration.
Patil R, Palkar S, Mishra A, Arankalle V. Patil R, et al. Vaccines (Basel). 2024 Sep 11;12(9):1039. doi: 10.3390/vaccines12091039. Vaccines (Basel). 2024. PMID: 39340071 Free PMC article.
Diagnosis with Metagenomic Next-Generation Sequencing (mNGS) technology and real-time PCR for SARS-CoV-2 Omicron detection using various nasopharyngeal swabs in SARS-CoV-2 Omicron.
Li S, Zhang Y, Tong P, Yang W. Li S, et al. PLoS One. 2024 Aug 6;19(8):e0305289. doi: 10.1371/journal.pone.0305289. eCollection 2024. PLoS One. 2024. PMID: 39106263 Free PMC article.
Performance evaluation of SARS-CoV-2 rapid diagnostic tests in Nigeria: A cross-sectional study.
Omonkhua AA, Faneye A, Akinwande KS, Evaezi O, Shehu NY, Onayade A, Ochu CL, Popoola M, Emmanuel N, Ojo T, Ohonsi C, Abubakar A, Odeh E, Akinduti P, Folarin O, Bimba JS, Igumbor E, Elimian K, Edem VF, Pam D L, Olusola T, Ntoimo L, Olugbile M, Opayele AV, Kida I, David S, Onyeaghala A, Igbarumah I, Maduka O, Mahmoud MA, El-Fulatty AR, Olaleye DO, Simon O, Osaigbovo II, Obaseki DE, Tolulupe A, Happi C, Jibrin YB, Okonofua F, Eliya T, Simji G, Abi IJ, Ameh E, Maigari IM, Alhaji S, Adetifa I, Salako B, Bogoro S, Ihekweazu C, Odaibo GN; COVID-19 RDT Validation in Nigeria (CORVAN) study group. Omonkhua AA, et al. PLOS Glob Public Health. 2024 Jul 15;4(7):e0003371. doi: 10.1371/journal.pgph.0003371. eCollection 2024. PLOS Glob Public Health. 2024. PMID: 39008485 Free PMC article.

See all "Cited by" articles

References

1. Baden LR, El Sahly HM, Essink B, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med. 2021;384:403–416. - PMC - PubMed
1. Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med. 2020;383:2603–2615. - PMC - PubMed
1. Voysey M, Costa Clemens SA, Madhi SA, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2020;397:99–111. - PMC - PubMed
1. Logunov DY, Dolzhikova IV, Shcheblyaokov DV, et al. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVIC-19 vaccine: an interim analysis of a randomized controlled phase 3 trial in Russia. Lancet. 2021 doi: 10.1016/S0140-6736(21)00234-8. published online Feb 2. - DOI - PMC - PubMed
1. Emary KRW, Golubchik T, Aley PK, et al. Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 VOC 202012/01 (B.1.1.7) SSRN. 2021 doi: 10.2139/ssrn.3779160. published online Feb 4. - DOI - PubMed

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions

LinkOut - more resources

Full Text Sources
Other Literature Sources
- The Lens - Patent Citations Database
- scite Smart Citations
Medical
- MedlinePlus Health Information
Miscellaneous
- NCI CPTAC Assay Portal

[1] Baden LR, El Sahly HM, Essink B, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med. 2021;384:403–416. - PMC - PubMed

[2] Baden LR, El Sahly HM, Essink B, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med. 2021;384:403–416. - PMC - PubMed

[3] Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med. 2020;383:2603–2615. - PMC - PubMed

[4] Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med. 2020;383:2603–2615. - PMC - PubMed

[5] Voysey M, Costa Clemens SA, Madhi SA, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2020;397:99–111. - PMC - PubMed

[6] Voysey M, Costa Clemens SA, Madhi SA, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2020;397:99–111. - PMC - PubMed

[7] Logunov DY, Dolzhikova IV, Shcheblyaokov DV, et al. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVIC-19 vaccine: an interim analysis of a randomized controlled phase 3 trial in Russia. Lancet. 2021 doi: 10.1016/S0140-6736(21)00234-8. published online Feb 2. - DOI - PMC - PubMed

[8] Logunov DY, Dolzhikova IV, Shcheblyaokov DV, et al. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVIC-19 vaccine: an interim analysis of a randomized controlled phase 3 trial in Russia. Lancet. 2021 doi: 10.1016/S0140-6736(21)00234-8. published online Feb 2. - DOI - PMC - PubMed

[9] Emary KRW, Golubchik T, Aley PK, et al. Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 VOC 202012/01 (B.1.1.7) SSRN. 2021 doi: 10.2139/ssrn.3779160. published online Feb 4. - DOI - PubMed

[10] Emary KRW, Golubchik T, Aley PK, et al. Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 VOC 202012/01 (B.1.1.7) SSRN. 2021 doi: 10.2139/ssrn.3779160. published online Feb 4. - DOI - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

SARS-CoV-2 variants and ending the COVID-19 pandemic

Affiliations

SARS-CoV-2 variants and ending the COVID-19 pandemic

Authors

Affiliations

Similar articles

Cited by

References

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical

Miscellaneous